JP2021514206A5 - - Google Patents
Info
- Publication number
- JP2021514206A5 JP2021514206A5 JP2020566543A JP2020566543A JP2021514206A5 JP 2021514206 A5 JP2021514206 A5 JP 2021514206A5 JP 2020566543 A JP2020566543 A JP 2020566543A JP 2020566543 A JP2020566543 A JP 2020566543A JP 2021514206 A5 JP2021514206 A5 JP 2021514206A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- human
- binding
- cancer
- cells
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024135326A JP2024170430A (ja) | 2018-02-20 | 2024-08-14 | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632756P | 2018-02-20 | 2018-02-20 | |
| US62/632,756 | 2018-02-20 | ||
| PCT/US2019/018748 WO2019164929A1 (en) | 2018-02-20 | 2019-02-20 | Antibody variable domains targeting cd33, and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135326A Division JP2024170430A (ja) | 2018-02-20 | 2024-08-14 | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021514206A JP2021514206A (ja) | 2021-06-10 |
| JP2021514206A5 true JP2021514206A5 (https=) | 2022-03-10 |
| JPWO2019164929A5 JPWO2019164929A5 (https=) | 2022-03-10 |
| JP7539840B2 JP7539840B2 (ja) | 2024-08-26 |
Family
ID=67688433
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566543A Active JP7539840B2 (ja) | 2018-02-20 | 2019-02-20 | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
| JP2024135326A Pending JP2024170430A (ja) | 2018-02-20 | 2024-08-14 | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135326A Pending JP2024170430A (ja) | 2018-02-20 | 2024-08-14 | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200376034A1 (https=) |
| EP (1) | EP3755348A4 (https=) |
| JP (2) | JP7539840B2 (https=) |
| KR (1) | KR20200133222A (https=) |
| CN (1) | CN111989109A (https=) |
| AU (1) | AU2019225740A1 (https=) |
| BR (1) | BR112020016944A2 (https=) |
| CA (1) | CA3091764A1 (https=) |
| CL (2) | CL2020002143A1 (https=) |
| EA (1) | EA202091976A1 (https=) |
| IL (1) | IL276776A (https=) |
| MX (1) | MX2020008683A (https=) |
| PE (1) | PE20211224A1 (https=) |
| SG (1) | SG11202007943RA (https=) |
| TW (1) | TW201945390A (https=) |
| WO (1) | WO2019164929A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| IL268755B2 (en) | 2017-02-20 | 2025-12-01 | Dragonfly Therapeutics Inc | Proteins that bind her2, nkg2d, and cd16 |
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| WO2019164930A1 (en) * | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| EP3962527A4 (en) | 2019-04-30 | 2023-11-01 | Senti Biosciences, Inc. | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF |
| MX2022004430A (es) * | 2019-10-15 | 2022-07-19 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3). |
| MX2022013944A (es) * | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| EP4291233A4 (en) * | 2021-02-10 | 2025-05-21 | Wugen, Inc. | POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| US20250082681A1 (en) * | 2021-07-30 | 2025-03-13 | Nanjing Legend Biotech Co., Ltd. | Antibodies against cll1 and constructs thereof |
| WO2023015322A1 (en) * | 2021-08-06 | 2023-02-09 | Actinium Pharmaceuticals, Inc. | Radioconjugates targeting cd33 in the treatment of cancers |
| WO2023056252A1 (en) * | 2021-09-29 | 2023-04-06 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and baff-r |
| CN118591388A (zh) * | 2021-09-29 | 2024-09-03 | 摩德斯医疗股份有限公司 | 抗原结合多肽、抗原结合多肽复合物及其使用方法 |
| US20250381255A1 (en) * | 2022-02-17 | 2025-12-18 | Anokion Sa | Anti-asgr1 polypeptides and methods of use for immune tolerance |
| WO2024249235A1 (en) * | 2023-06-01 | 2024-12-05 | Abbvie Inc. | Anti-human cd33 bet degrader antibody-drug conjugates |
| WO2025233431A1 (en) * | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7676300A (en) * | 1999-10-12 | 2001-04-23 | Cambridge Antibody Technology Limited | Human anti-adipocyte monoclonal antibodies and their use |
| JOP20080381B1 (ar) * | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| EA201691214A1 (ru) * | 2013-12-13 | 2016-12-30 | Дженентек, Инк. | Антитела к cd33 и иммуноконъюгаты |
| CN107708733B (zh) * | 2015-04-07 | 2022-11-15 | 艾利妥 | 抗分拣蛋白抗体和其使用方法 |
| JP7497953B2 (ja) * | 2015-06-12 | 2024-06-11 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| JP7376977B2 (ja) * | 2015-06-12 | 2023-11-09 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
-
2019
- 2019-02-20 EP EP19757093.0A patent/EP3755348A4/en active Pending
- 2019-02-20 CN CN201980025297.8A patent/CN111989109A/zh active Pending
- 2019-02-20 CA CA3091764A patent/CA3091764A1/en active Pending
- 2019-02-20 PE PE2020001434A patent/PE20211224A1/es unknown
- 2019-02-20 TW TW108105692A patent/TW201945390A/zh unknown
- 2019-02-20 BR BR112020016944-7A patent/BR112020016944A2/pt not_active Application Discontinuation
- 2019-02-20 KR KR1020207026825A patent/KR20200133222A/ko active Pending
- 2019-02-20 AU AU2019225740A patent/AU2019225740A1/en not_active Abandoned
- 2019-02-20 SG SG11202007943RA patent/SG11202007943RA/en unknown
- 2019-02-20 WO PCT/US2019/018748 patent/WO2019164929A1/en not_active Ceased
- 2019-02-20 MX MX2020008683A patent/MX2020008683A/es unknown
- 2019-02-20 JP JP2020566543A patent/JP7539840B2/ja active Active
- 2019-02-20 US US16/971,098 patent/US20200376034A1/en not_active Abandoned
- 2019-02-20 EA EA202091976A patent/EA202091976A1/ru unknown
-
2020
- 2020-08-18 IL IL276776A patent/IL276776A/en unknown
- 2020-08-19 CL CL2020002143A patent/CL2020002143A1/es unknown
-
2023
- 2023-07-19 CL CL2023002105A patent/CL2023002105A1/es unknown
-
2024
- 2024-08-14 JP JP2024135326A patent/JP2024170430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514206A5 (https=) | ||
| JPWO2019164929A5 (https=) | ||
| EP3341020B1 (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
| CN110291109B (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| RU2457219C2 (ru) | Антигенсвязывающие молекулы, которые связывают рецептор эпидермального фактора роста (egfr), кодирующие их векторы и их применение | |
| US11639388B2 (en) | CD3 antigen binding fragment and application thereof | |
| CN113015749A (zh) | 靶向cd3的抗体、双特异性抗体及其用途 | |
| WO2021048725A1 (en) | Anti-pd-l1 single-domain antibody and derivatives and use thereof | |
| CA3092456A1 (en) | Anti-tigit antibody and use thereof | |
| JP2023511482A (ja) | Ｃｄ２７６抗原の抗体ターゲティング、および他のモジュレーター、ならびにその使用 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2008529489A5 (https=) | ||
| EP3882276A1 (en) | Bispecific antibody, preparation method therefor and application thereof | |
| JP2020527136A (ja) | チェックポイントインヒビター二重特異性抗体 | |
| RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека | |
| WO2017071625A1 (zh) | 一种抗pd-1单克隆抗体、其药物组合物及其用途 | |
| JP2013528357A5 (https=) | ||
| JP2018506277A5 (https=) | ||
| CN111182919A (zh) | 抗cd137抗体 | |
| JP6952888B2 (ja) | 抗ｐａｃａｐ抗体 | |
| JP7495409B2 (ja) | 改善された抗ｆｌｔ３抗原結合タンパク質 | |
| AU2016319433A1 (en) | Anti-EphA4 antibody | |
| JPWO2019183551A5 (https=) | ||
| EP4667491A1 (en) | Anti-cntn4 antibody and uses thereof | |
| KR20250130296A (ko) | 항-ccr8 항체 및 이의 용도 |